195 related articles for article (PubMed ID: 38337473)
1. e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response.
Marcé S; Méndez A; Xicoy B; Estrada N; Cabezón M; Sturla AL; García MR; Angona A; Amat P; Escribano Serrat S; Scalzulli E; Morgades M; Senín A; Hernández-Boluda JC; Ferrer-Marín F; Anguita E; Cortés M; Plensa E; Breccia M; García-Gutierrez V; Zamora L;
J Clin Med; 2024 Jan; 13(3):. PubMed ID: 38337473
[TBL] [Abstract][Full Text] [Related]
2. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
3. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
Marcé S; Xicoy B; García O; Cabezón M; Estrada N; Vélez P; Boqué C; Sagüés M; Angona A; Teruel-Montoya R; Ferrer-Marín F; Amat P; Hernández-Boluda JC; Ibarra MM; Anguita E; Cortés M; Fernández-Ruiz A; Fontanals S; Zamora L; On Behalf Of The Grupo Español de Leucemia Mieloide Crónica Gelmc
J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300312
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Transcript-Type
Molica M; Abruzzese E; Breccia M
Mediterr J Hematol Infect Dis; 2020; 12(1):e2020062. PubMed ID: 32952973
[TBL] [Abstract][Full Text] [Related]
5. Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis.
Chen K; Ruan Y; Tian K; Xiong P; Xia N; Li J; Huang W; Cao F; Chen Q
Front Oncol; 2022; 12():841546. PubMed ID: 35223524
[TBL] [Abstract][Full Text] [Related]
6. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
7. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
Ercaliskan A; Eskazan AE
Cancer; 2018 Oct; 124(19):3806-3818. PubMed ID: 29694669
[TBL] [Abstract][Full Text] [Related]
8. Effect of
Park H; Kim HJ; Sohn SK; Baik Y; Kim D; Lee SY; Kong JH; Kim H; Shin DY; Ahn JS; Park J; Park S; Kim I
Ther Adv Hematol; 2023; 14():20406207231205637. PubMed ID: 37929079
[TBL] [Abstract][Full Text] [Related]
9. Influence of major
Genthon A; Nicolini FE; Huguet F; Colin-Gil C; Berger M; Saugues S; Janel A; Hayette S; Cohny-Makhoul P; Cadoux N; Cayuela JM; Campos L; Guyotat D; Flandrin-Gresta P
Oncotarget; 2020 Jun; 11(26):2560-2570. PubMed ID: 32655840
[TBL] [Abstract][Full Text] [Related]
10. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
[TBL] [Abstract][Full Text] [Related]
11. [Analysis the influence factors of treatment free remission outcome with chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitors].
Zhao HF; Zhang Y; Dang LX; Liang JL; Chen SX; Guo Z; Li YL; Zu RR; Gui XD; Wei YP; Song Y
Zhonghua Yi Xue Za Zhi; 2022 May; 102(20):1523-1529. PubMed ID: 35692068
[No Abstract] [Full Text] [Related]
12. Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.
Su YJ; Kuo MC; Chen TY; Wang MC; Yang Y; Ma MC; Lin TL; Lin TH; Chang H; Teng CJ; Hsiao PC; Chen CC; Wang PN; Shih LY
Cancer Sci; 2022 Oct; 113(10):3518-3527. PubMed ID: 35869805
[TBL] [Abstract][Full Text] [Related]
13. Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
Pagnano KBB; Miranda EC; Delamain MT; Duarte GO; de Paula EV; Lorand-Metze I; de Souza CA
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):728-733. PubMed ID: 28822797
[TBL] [Abstract][Full Text] [Related]
14. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
[TBL] [Abstract][Full Text] [Related]
15. Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
Saugues S; Lambert C; Daguenet E; Ansah HJ; Turhan A; Huguet F; Guerci-Bresler A; Tchirkov A; Hamroun D; Hermet E; Pereira B; Berger MG
Ann Hematol; 2022 Oct; 101(10):2241-2255. PubMed ID: 36040480
[TBL] [Abstract][Full Text] [Related]
16. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
Shanmuganathan N; Pagani IS; Ross DM; Park S; Yong ASM; Braley JA; Altamura HK; Hiwase DK; Yeung DT; Kim DW; Branford S; Hughes TP
Blood; 2021 Mar; 137(9):1196-1207. PubMed ID: 32871588
[TBL] [Abstract][Full Text] [Related]
17. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
Rostami G; Hamid M; Jalaeikhoo H
Gene; 2017 Sep; 627():202-206. PubMed ID: 28627443
[TBL] [Abstract][Full Text] [Related]
18. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
Lucas CM; Harris RJ; Giannoudis A; Davies A; Knight K; Watmough SJ; Wang L; Clark RE
Haematologica; 2009 Oct; 94(10):1362-7. PubMed ID: 19713230
[TBL] [Abstract][Full Text] [Related]
19. Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients.
Etienne G; Dulucq S; Bauduer F; Adiko D; Lifermann F; Dagada C; Lenoir C; Schmitt A; Klein E; Madene S; Fort MP; Bijou F; Moldovan M; Turcq B; Robbesyn F; Durrieu F; Versmée L; Katsahian S; Faberes C; Lascaux A; Mahon FX
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899879
[No Abstract] [Full Text] [Related]
20. Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.
Iurlo A; Cattaneo D; Consonni D; Castagnetti F; Miggiano MC; Binotto G; Bonifacio M; Rege-Cambrin G; Tiribelli M; Lunghi F; Gozzini A; Pregno P; Abruzzese E; Capodanno I; Bucelli C; Pizzuti M; Artuso S; Iezza M; Scalzulli E; La Barba G; Maggi A; Russo S; Elena C; Scortechini AR; Tafuri A; Latagliata R; Caocci G; Bocchia M; Galimberti S; Luciano L; Fava C; Foà R; Saglio G; Rosti G; Breccia M
Front Pharmacol; 2023; 14():1154377. PubMed ID: 37033642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
